Baxter International (NYSE:BAX) Releases FY20 Earnings Guidance
Baxter International (NYSE:BAX) issued an update on its FY20 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $3.00-3.10 for the period, compared to the Thomson Reuters consensus estimate of $3.31. The company issued revenue guidance of (1%) – 1% to $11.6-11.8 billion, compared to the consensus revenue estimate of $11.71 billion.Baxter International also updated its FY 2020
Pre-Market guidance to 3.00-3.10 EPS.
Shares of BAX opened at $86.38 on Friday. The business’s 50 day moving average is $86.00 and its two-hundred day moving average is $86.95. Baxter International has a 52-week low of $69.10 and a 52-week high of $95.19. The firm has a market cap of $43.62 billion, a price-to-earnings ratio of 26.10, a PEG ratio of 2.75 and a beta of 0.84. The company has a quick ratio of 2.19, a current ratio of 2.74 and a debt-to-equity ratio of 0.84.
Baxter International (NYSE:BAX) last announced its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.71 by ($0.07). Baxter International had a net margin of 8.10% and a return on equity of 21.02%. The business had revenue of $2.72 billion during the quarter, compared to analyst estimates of $2.86 billion. During the same period in the previous year, the company earned $0.89 earnings per share. The business’s revenue for the quarter was down 4.3% on a year-over-year basis. On average, equities analysts expect that Baxter International will post 3.05 earnings per share for the current fiscal year.
A number of equities analysts have issued reports on BAX shares. Credit Suisse Group reaffirmed a buy rating and issued a $99.00 target price on shares of Baxter International in a research report on Friday. JPMorgan Chase & Co. upped their price target on Baxter International from $94.00 to $96.00 and gave the company an overweight rating in a research report on Tuesday, April 28th. KeyCorp upped their price target on Baxter International from $92.00 to $98.00 and gave the company an overweight rating in a research report on Friday, May 1st. Oppenheimer reissued a buy rating on shares of Baxter International in a research report on Thursday. Finally, UBS Group upped their price target on Baxter International from $95.00 to $103.00 and gave the company a buy rating in a research report on Friday, May 1st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the stock. Baxter International currently has a consensus rating of Buy and a consensus target price of $96.72.
In related news, SVP Andrew Frye sold 3,742 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $91.00, for a total transaction of $340,522.00. Following the completion of the transaction, the senior vice president now directly owns 16,216 shares in the company, valued at approximately $1,475,656. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director John D. Forsyth sold 1,500 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $82.95, for a total value of $124,425.00. Following the completion of the transaction, the director now directly owns 35,398 shares of the company’s stock, valued at approximately $2,936,264.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 77,583 shares of company stock valued at $6,613,932. 0.13% of the stock is owned by company insiders.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Further Reading: Why Invest in Dividend Achievers?
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.